ArticleHepatology international2022
Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study.
Article in Hepatology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis.Human vaccines & immunotherapeutics · 2024Pooled it
- Thrombotic risk trajectories in patients with coronary artery disease before and during COVID-19.iScience · 2026Article
- COVID-19 Vaccination in Liver Cirrhosis: Safety and Immune and Clinical Responses.GE Portuguese journal of gastroenterology · 2024Article
- Efficacy, immunogenicity, and safety of COVID-19 vaccines in individuals with liver cirrhosis: a rapid review and meta-analysis.Clinical and experimental vaccine research · 2024Review
- Dynamic Humoral Immune Response to Primary and Booster Inactivated SARS-CoV-2 Vaccination in Patients with Cirrhosis.Journal of clinical and translational hepatology · 2023Article
- Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases.Virologica Sinica · 2023Article
- SARS-CoV-2 Vaccine Uptake among Patients with Chronic Liver Disease: A Cross-Sectional Analysis in Hebei Province, China.Vaccines · 2023Article
- Vaccination in liver diseases and liver Transplantation: Recommendations, implications and opportunities in the post-covid era.JHEP reports : innovation in hepatology · 2023Review
- Safety and Immunogenicity of Anti-SARS-CoV-2 Booster Dose in Patients with Chronic Liver Disease.Journal of clinical medicine · 2023Article
- Efficacy, Safety and Immunogenicity of Anti-SARS-CoV-2 Vaccines in Patients with Cirrhosis: A Narrative Review.Vaccines · 2023Review
- SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes.Gut and liver · 2023Review
- Durability of immune response after SARS-CoV-2 vaccination in patients with chronic liver disease.Frontiers in immunology · 2023Article
- Analysis of neutralizing antibodies to COVID-19 inactivated or subunit recombinant vaccines in hospitalized patients with liver dysfunction.Frontiers in immunology · 2023Article
- COVID-19 vaccination and liver disease.World journal of gastroenterology · 2022Review
- [Efficacy and safety of inactivated novel coronavirus vaccine inoculation in patients with chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-centre retrospective cohort.Emerging microbes & infections · 2022Article
- Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study.The Journal of infection · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
67 authors at 20 institutions in 1 country.
Funding
Abstract
backgroundData on safety and immunogenicity of coronavirus disease 2019 (COVID-19) vaccination in patients with compensated (C-cirrhosis) and decompensated cirrhosis (D-cirrhosis) are limited.
methodsIn this prospective multicenter study, adult participants with C-cirrhosis and D-cirrhosis were enrolled and received two doses of inactivated whole-virion COVID-19 vaccines. Adverse events were recorded within 14 days after any dose of vaccination, and serum samples of enrolled patients were collected and tested for SARS-CoV-2 neutralizing antibodies at least 14 days after the second dose. Risk factors for negative neutralizing antibody were analyzed.
resultsIn total, 553 patients were enrolled from 15 centers in China, including 388 and 165 patients with C-cirrhosis and D-cirrhosis. The vaccines were well tolerated, most adverse reactions were mild and transient, and injection site pain (23/388 [5.9%] vs 9/165 [5.5%]) and fatigue (5/388 [1.3%] vs 3/165 [1.8%]) were the most frequently local and systemic adverse events in both the C-cirrhosis and D-cirrhosis groups. Overall, 4.4% (16/363) and 0.3% (1/363) of patients were reported Grades 2 and 3 alanine aminotransferase (ALT) elevations (defined as ALT > 2 upper limit of normal [ULN] but ≤ 5 ULN, and ALT > 5 ULN, respectively). The positive rates of COVID-19 neutralizing antibodies were 71.6% (278/388) and 66.1% (109/165) in C-cirrhosis and D-cirrhosis groups. Notably, Child-Pugh score of B and C levels was an independent risk factor of negative neutralizing antibody.
conclusionsInactivated COVID-19 vaccinations are safe with acceptable immunogenicity in cirrhotic patients, and Child-Pugh score of B and C levels is associated with hyporesponsive to COVID-19 vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.